Sandoz Group Lays Out New FY30 Targets, Bio100 Goal

MT Newswires · 1d ago
01:29 AM EDT, 09/08/2026 (MT Newswires) -- Sandoz Group (SDZ.SW) on Tuesday outlined new 2030 targets ahead of its capital markets day, powered by a planned surge in its biosimilars portfolio. The Swiss drugmaker is aiming for a mid-to-high single-digit compound annual growth in net sales at constant currencies between 2025 and 2030, which will more than double its topline. The new midterm outlook is underpinned by the Bio100 ambition, which is the group's commitment to raise biosimilars to over 100 by 2040 from 13. Sandoz reiterated its midterm guidance to 2028.